TR200201182T2 - Chlorite solutions for the treatment of cancer and other diseases - Google Patents

Chlorite solutions for the treatment of cancer and other diseases

Info

Publication number
TR200201182T2
TR200201182T2 TR2002/01182T TR200201182T TR200201182T2 TR 200201182 T2 TR200201182 T2 TR 200201182T2 TR 2002/01182 T TR2002/01182 T TR 2002/01182T TR 200201182 T TR200201182 T TR 200201182T TR 200201182 T2 TR200201182 T2 TR 200201182T2
Authority
TR
Turkey
Prior art keywords
cancer
treatment
stabilized chlorite
chlorite matrix
diseases
Prior art date
Application number
TR2002/01182T
Other languages
Turkish (tr)
Inventor
W. Kuhne Frederich
Kodelja V�Tam
Original Assignee
Oxo Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxo Chemie Ag filed Critical Oxo Chemie Ag
Publication of TR200201182T2 publication Critical patent/TR200201182T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Bagisiklik yanitlarini denetlemek ve kanseri tedavi etmek için kararli hale getirilmis bir klorit matrisinin kullanim yöntemleri anlatilmistir. Kararli hale getirilmis klorit matrisi, buna gereksinimi olan bir memeliye uygulandiginda, interferon gammaya benzer bir sekilde bagisiklik hücrelerini etkinlestirebilir, ama tümör nekroz alfa gibi iltihap olusturucu ve sokla baglantili sitokinlerin üretimini etkilemez. Kararli hale getirilmis klorit matrisi ayrica, makrofajlar içindeki DCC proteininin ekspresyonunu da düzenler; burada sözkonusu DCC proteini, ekspresyonu neoplazma dönüsümüne iliskin olan bir proteindir. Dolayisiyla, kararli hale getirilmis klorit matrisi, bagisiklik denetleyici bir etken olarak ve kanser tedavisinde yararlidir.The methods of using a stabilized chlorite matrix to control immune responses and treat cancer are described. When the stabilized chlorite matrix is applied to a mammal that needs it, it can activate immune cells similar to interferon gamma, but does not affect the production of inflammatory and shock-related cytokines, such as tumor necrosis alpha. The stabilized chlorite matrix also regulates the expression of the DCC protein in macrophages; wherein said DCC protein is a protein whose expression is related to the transformation of neoplasm. Therefore, the stabilized chlorite matrix is useful as a control agent of immunity and in the treatment of cancer.

TR2002/01182T 1999-08-18 2000-08-18 Chlorite solutions for the treatment of cancer and other diseases TR200201182T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14942999P 1999-08-18 1999-08-18

Publications (1)

Publication Number Publication Date
TR200201182T2 true TR200201182T2 (en) 2002-08-21

Family

ID=22530238

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01182T TR200201182T2 (en) 1999-08-18 2000-08-18 Chlorite solutions for the treatment of cancer and other diseases

Country Status (14)

Country Link
EP (1) EP1408994A2 (en)
KR (1) KR20020038728A (en)
CN (1) CN1378456A (en)
AU (1) AU6913200A (en)
CA (1) CA2382293A1 (en)
IL (1) IL148189A0 (en)
MX (1) MXPA02001724A (en)
NO (1) NO20020751L (en)
NZ (1) NZ517673A (en)
PL (1) PL353769A1 (en)
RU (1) RU2002106824A (en)
TR (1) TR200201182T2 (en)
WO (1) WO2001012205A2 (en)
ZA (1) ZA200201726B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687238B1 (en) 2003-11-21 2009-12-09 CytoTools AG Reactive chlorine compounds, the derivatives, anions, and salts thereof, method for the production thereof, and use thereof
EP2428213A1 (en) * 2005-07-21 2012-03-14 Nuvo Research AG Stabilized chlorite solutions in combination with fluoropyrimidines for use in cancer treatment
BR112014015333A2 (en) 2011-12-22 2017-06-13 Nuvo Res Gmbh chlorite or chlorate liposomal compositions
CN112386606A (en) * 2019-08-19 2021-02-23 卢序 Use of an oxidizing agent having a second messenger effect to increase the active oxidation pressure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3515749A1 (en) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg USE OF A STABILIZED CHLORITE MATRIX SOLUTION IN INFECTIOUS CONDITIONS
DE3515748A1 (en) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg USE OF ISOTON CHLORITE MATRIX SOLUTION IN TUMOR TREATMENT
DE69821506T2 (en) * 1997-10-06 2004-12-16 Oxo Chemie Ag USE OF A CHEMICALLY STABILIZED CHLORITE SOLUTION FOR INHIBITING THE ANTI-SPECIFIC IMMUNE RESPONSE
BR0008369A (en) * 1999-02-19 2001-11-06 Kurt Wilhelm Stahl peroxycloric acid, anion derivatives, their salts, and procedure for their manufacture and application

Also Published As

Publication number Publication date
NO20020751L (en) 2002-04-17
EP1408994A2 (en) 2004-04-21
WO2001012205A3 (en) 2001-09-13
RU2002106824A (en) 2003-11-27
PL353769A1 (en) 2003-12-01
AU6913200A (en) 2001-03-13
IL148189A0 (en) 2002-09-12
KR20020038728A (en) 2002-05-23
ZA200201726B (en) 2003-12-31
MXPA02001724A (en) 2004-09-06
CN1378456A (en) 2002-11-06
CA2382293A1 (en) 2001-02-22
WO2001012205A2 (en) 2001-02-22
NO20020751D0 (en) 2002-02-15
NZ517673A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
NO20032759D0 (en) 2-phenylbenzimidazoles and imidazo [4,5] pyridines as SDSI / CHK2 inhibitors and adjuvants in chemotherapy or radiation therapy in the treatment of cancer
DK1132393T3 (en) L-Ribavirin and its uses
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
NO20026245D0 (en) Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytokine uptake agents
MY139226A (en) Compositions and methods for wt1 specific immunotherapy
NO20050640L (en) Ruthenium anticancer complexes
ATE120372T1 (en) ANTIBODIES FOR ANTILYMPHOCYTE ANTIBODIES THERAPY.
DE69620639D1 (en) MERCAPTOALKYLPEPTIDYL COMPOUNDS WITH AN IMIDAZOLE SUBSTITUENT AND THEIR USE AS INHIBITORS OF THE MATRIX METALLOPROTEINASES (MMP) AND / OR THE TUMOR NECROSIS FACTOR (TNF)
TR200201182T2 (en) Chlorite solutions for the treatment of cancer and other diseases
HK1033910A1 (en) Use of erythropoietin in the treatment of multiple myeloma
ATE17719T1 (en) SULFUR-SUBSTITUTED PHENOXYPYRIDINE WITH ANTIVIRAL ACTIVITY.
EP1178796A4 (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
ES2058343T3 (en) DISUBSTITUTED PIRIDINES.
WO2003026580A3 (en) Interactive therapeutic enclosures
NO994750D0 (en) Anti-Fas antibodies
TR199903074T2 (en) HMG CoA and farnesyl transfer inhibitors in cancer therapy.
EP0775157A4 (en) Human serum albumin-porphyrin complexes with the ability to bind oxygen and therapeutic uses thereof
ATE285247T1 (en) CANCER THERAPY WITH LYMPHOTOXIN
DK0918545T3 (en) tumor Treatment
CN210329934U (en) Furniture supporting leg with voice recognition function and furniture
DE60042273D1 (en) ANTITUMAN ANTIBODIES, PROTEINS AND ITS USE
MY103499A (en) Acyl derivatives of hydroxy pyrimidines
WO2001042431A3 (en) Regulation of human mitochondrial deformylase
DE3686472T2 (en) CARDIOTONIC PHENYLOXAZOLONE.
DE68902396T2 (en) 1H-INDAZOL-3-ACETIC ACID AS ALDOSE REDUCTASE INHIBITORS.